Compare BLZE & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | RIGL |
|---|---|---|
| Founded | 2007 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 762.0M | 884.9M |
| IPO Year | 2021 | 2000 |
| Metric | BLZE | RIGL |
|---|---|---|
| Price | $13.23 | $45.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $7.60 | ★ $45.67 |
| AVG Volume (30 Days) | ★ 1.7M | 200.8K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 58.56 | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | $145,835,000.00 | ★ $294,282,000.00 |
| Revenue This Year | $10.16 | N/A |
| Revenue Next Year | $10.91 | $12.75 |
| P/E Ratio | ★ N/A | $35.30 |
| Revenue Growth | 14.27 | ★ 64.15 |
| 52 Week Low | $3.26 | $24.84 |
| 52 Week High | $23.99 | $52.24 |
| Indicator | BLZE | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 42.46 | 53.35 |
| Support Level | $12.15 | $40.50 |
| Resistance Level | $14.19 | $49.50 |
| Average True Range (ATR) | 0.69 | 1.46 |
| MACD | -0.03 | -0.53 |
| Stochastic Oscillator | 40.55 | 34.48 |
Backblaze Inc offers a cloud storage platform designed to help businesses and consumers store, use, and protect their data. The company delivers its services through the Backblaze Storage Cloud platform, a purpose-built, web-scale software architecture operating on commodity hardware. Backblaze's offerings include B2 Cloud Storage, an Infrastructure-as-a-Service (IaaS) solution, and Computer Backup, a Software-as-a-Service (SaaS) solution. Its customer base includes individuals, developers, MSPs, small and medium-sized businesses, and large enterprises across industries, academic institutions, government agencies, and other enterprises. Geographically, the company generates maximum revenue from its business in the United States, followed by the United Kingdom, Canada, and other markets.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.